Goldman Sachs’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Goldman Sachs’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-98,800	Closed	-$1.93M	–	5586
2018 Q4	$1.93M	Buy	+98,800	New	+$2.03M	﹤0.01%	3550
2018 Q2	–	Sell	-61,200	Closed	-$2M	–	6177
2018 Q1	$2M	Buy	61,200 +34,200	+127%	+$1.5M	﹤0.01%	3603
2017 Q4	$1.31M	Sell	27,000 -2,800	-9%	-$142K	﹤0.01%	4128
2017 Q3	$1.61M	Buy	+29,800	New	+$1.75M	﹤0.01%	4163
2017 Q1	–	Sell	-65,000	Closed	-$1.46M	–	7122
2016 Q4	$1.46M	Hold	65,000	–	–	﹤0.01%	4132
2016 Q3	$1.48M	Buy	+65,000	New	+$1.53M	﹤0.01%	4067
2016 Q2	–	Sell	-250,000	Closed	-$5.1M	–	7367
2016 Q1	$5.1M	Buy	+250,000	New	+$7.93M	﹤0.01%	2710

Goldman Sachs's PTLA Position: Q3 2020 in Review

Goldman Sachs sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 3,590,091 shares — an estimated $64.6M sold.

Goldman Sachs first reported a position in PTLA in Q2 2013 and held it in 28 quarters. The position peaked at $64.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Goldman Sachs reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Goldman Sachs sold 3,590,091 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $64.6M.
Goldman Sachs first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
Goldman Sachs's Portola Pharmaceuticals, Inc. position peaked at $64.6M in Q2 2020.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.